Combined Influence of Genetic Variants and Gene-gene Interaction on Sulfonylurea Efficacy in Type 2 Diabetic Patients

Abstract

Several genes have been shown to influence the response to sulfonylureas in previous studies. However, their interactions and combined genetic influence on sulfonylurea efficacy remain mostly unexplored. So the aim of this study was to examine the interactions of these published susceptibility alleles and access the potential utility of combining information for drug response prediction.

Methods: We genotyped 5 variants of these genes in a total of 747 diabetic patients enrolled in a trial of glibenclamide (CYP2C9, KCNJ11, TCF7L2, KCNQ1 and CDKN2A/2B gene). All the patients were followed for 48 weeks. Treatment failure was fasting blood glucose level≥7.0 mmol/L. A Cox regression model was used to evaluate the relationship between genetic variants and treatment failure over a period of 48 weeks. The receiver operating characteristic (ROC) curve, the area under the curve (AUC) and the multifactor dimensionality reduction method (MDR) analyses were used to assess the gene-gene interaction and also the predictive power of the combined variants.

Results: The relationship beween risk alleles and FBG reduction at the end of the first month was not significant (Low Risk Group 10.8% (1.2–20.7%), Middle Risk Group 10.7% (1.3–21.1%), High Risk Group 8.51% (− 0.1–18.4%), P=0.212). After adjusting for sex, age, BMI, total dose of glibenclamide and baseline HbA1c, Cox regression showed a borderline significant association between the number of risk alleles and glibenclamide treatment failure (HR=1.125, 95%CI 1.016–1.246, P=0.023). There was potential gene-gene interaction between KCNJ11 and CDKN2A/2B gene using MDR method. The area under the ROC curve was 0.547, and the testing balanced accuracy of the best genetic model in MDR analysis was 0.5643.

Conclusion: Our study demonstrated that the combined genetic variants were borderline significantly associated with the efficacy of glibenclamide, and there are gene-gene interaction between KCNJ11 and CDKN2A/2B. More evidence was needed for increasing the predictive value of genetic variants on glibenclamide efficacy.

Key words

pharmacogenetics - sulfonylurea efficacy - type 2 diabetes

• References

• 1 Inzucchi SEBR, Buse JB. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) . Management of hyperglycemia in type 2 diabetes: a patient centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
• 2 Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101-109
• 3 Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263
• 4 Shon JH, Yoon YR, Kim KA et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics 2002; 12: 111-119
• 5 Suzuki K, Yanagawa T, Shibasaki T et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 2006; 72: 148-154
• 6 Takanashi K, Tainaka H, Kobayashi K et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104
• 7 Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clinical pharmacology and therapeutics 2010; 87: 52-56
• 8 Sesti G, Laratta E, Cardellini M et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 2334-2339
• 9 Javorsky M, Klimcakova L, Schroner Z et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 2012; 23: 245-249
• 10 Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008; 31: 1939-1944
• 11 Holstein A, Hahn M, Korner A et al. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet 2011; 12: 30
• 12 Pearson ER, Donnelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56: 2178-2182
• 13 Schroner Z, Javorsky M, Tkacova R et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 89-91
• 14 Schroner Z, Dobrikova M, Klimcakova L et al. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit 2011; 17: CR392-CR396
• 15 Ren Q, Han X, Tang Y et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia 2014; 57: 746-753
• 16 Yang Q, Khoury MJ, Botto L et al. Improving the Prediction of Complex Diseases by Testing for Multiple Disease-Susceptibility Genes. Am J Hum Genet 2003; 72: 636-649
• 17 McCarthy MI. Genomics, Type 2 Diabetes, and Obesity. NEJM 2010; 363: 2339-2350
• 18 Zeggini E, Scott LJ, Saxena R et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nature genetics 2008; 40: 638-645
• 19 Ji L, Tong X, Wang H et al. Efficacy and safety of traditional chinese medicine for diabetes: a double-blind, randomised, controlled trial. PLoS One 2013; 8: e56703
• 20 Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19: 376-382
• 21 Moore JH, Gilbert JC, Tsai CT et al. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 2006; 241: 252-261
• 22 Cho YM, Ritchie MD, Moore JH et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 2004; 47: 549-554
• 23 Ren Q, Han XY, Wang F et al. Exon sequencing and association analysis of polymorphisms in TCF7L2 with type 2 diabetes in a Chinese population. Diabetologia 2008; 51: 1146-1152
• 24 Wu Y, Li H, Loos RJ et al. Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. Diabetes 2008; 57: 2834-2842
• 25 tHart LM, van Haeften TW, Dekker JM et al. Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K(+) channel in the beta-cell. Diabetes 2002; 51: 3135-3138
• 26 Seino SIN, Namba N, Gonoi T. Molecular biology of the β-cell ATP-sensitive K+ channel. Diabetes Rev 1996; 4: 177-190
• 27 Janssens APM, Steyerberg EW, van Duijn CM. Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am J Hum Genet 2004; 74: 585-588
• 28 Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19: 376-382
• 29 Jason H, Moore JCG, Chia-Ti T et al. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. Journal of Theoretical Biology 2006; 241: 252-261
• 30 Talmud PJ, Hingorani AD, Cooper JA et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010; 340: b4838